Jubilant Ingrevia (JUBLINGREA) investor relations material

Executive summary

• Specialty Chemicals segment drove growth with double-digit EBITDA increases year-to-date, despite pricing pressures; Nutrition business maintained healthy volume growth, and Chemical Intermediates saw stable market share and volume gains.

• Q3 faced softer pricing, but strong volume growth offset the impact, keeping EBITDA margin at 13% as in Q2; nine-month revenue rose 3%, EBITDA up 8%, and PAT up 8% even after a one-time labor code expense.

• Consolidated revenue for Q3 was ₹105,099 lakhs, net profit at ₹4,690 lakhs; nine-month revenue was ₹320,967 lakhs, net profit ₹19,147 lakhs.

• Board recommended an interim dividend of 250% (₹2.5 per share), totaling ₹3,982 lakhs.

Financial highlights

• Q3 revenue was ₹1,051 crore, nearly flat year-over-year; volumes grew 9% despite macro headwinds.

• Q3 EBITDA was ₹136 crore, down 8% YoY; nine-month EBITDA was ₹436 crore, up 8% YoY.

• Q3 PAT after exceptional items was ₹47 crore; nine-month PAT was ₹191 crore, up 8% YoY.

• Basic and diluted EPS for Q3 was ₹3.0, and for nine months, ₹12.1.

• Energy costs reduced by 14% YTD; personnel and energy costs lower YoY.

Outlook and guidance

• Q4 FY26 expected to see continued growth in Specialty Chemicals and Nutrition, with partial recovery in Acetyls.

• Major CDMO order deliveries to commence in Q4 FY26, expected to accelerate growth; new multipurpose plant construction underway in Gajraula.

• Multi-year guidance targets at least 20% EBITDA CAGR; FY27 pivotal for capacity utilization and revenue ramp-up.

• FTAs with Europe and US anticipated to boost market share in coming quarters.